Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Subscriber?

Why Pharma, Private Equity Want to Reshape Lab Industry

It’s not about the lab test...but the expensive drug indicated by the test

FDA’s Gottlieb Favors Flexibility with LDTs, NGS
D.C. Circuit Court Reverses Medical Necessity Ruling

CEO SUMMARY: A disruptive force that involves precision medicine, pharmaceutical companies, and venture capital investors is poised to reshape the clinical laboratory industry. Genetic knowledge makes it possible to match cancer drugs to specific mutations. Pharma companies and professional investors recognize that control of diagnostic technologies and companion diagnostic tests enable them to gain better access …

Why Pharma, Private Equity Want to Reshape Lab Industry Read More »

To access this post, you must purchase The Dark Report.
FDA’s Gottlieb Favors Flexibility with LDTs, NGS
D.C. Circuit Court Reverses Medical Necessity Ruling

Comments

Volume XXV No. 5 – March 26, 2018

TABLE OF CONTENTS

COMMENTARY & OPINION BY R. LEWIS DARK

ARTICLES

INTELLIGENCE

Need A Group Membership? Company Discounts are Available!

Get More Information Now!
Facebook-f Twitter Linkedin-in

The Dark Report • 21806 Briarcliff Dr • Spicewood, TX 78669
Phone: 512-264-7103 • Toll Free Number: 800-560-6363
Email: customerservice@darkintelligencegroup.com

© 2022 The Dark Report. All rights reserved.

;

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

Privacy Policy: We will never share your personal information.